Shengqing Jiangzhuo Capsule Alleviates Intestinal Inflammation in Chronic Kidney Disease by Downregulating CHAC1 to Inactivate the HIF‐1 Pathway
Mediators of Inflammation · 2025
DOI: 10.1155/mi/2173234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, 2025. Verfasst von Zhibin Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Purification, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Clinical Research Academy of C…. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Drugs, Chinese Herbal, Inflammation, gamma-Glutamylcyclotransferase. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Traditional Chinese Medicine Bureau of Guangdong Province.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) imposes significant global health burdens. Shengqing Jiangzhuo (SQJZ) capsule possesses potential to alleviate CKD via gut‐kidney axis, with the specific role and mechanisms involving CHAC glutathione‐specific γ‐glutamylcyclotransferase 1 (CHAC1) and hypoxia‐inducible factor 1 (HIF‐1) signaling remaining unclear.
Methods
Adenine‐induced CKD rats were treated with SQJZ capsule for 4 weeks. The levels of blood urea nitrogen (BUN), serum creatinine (SCR), urine albumin/creatinine ratio (ACR), and inflammatory markers in colon tissues, including proinflammatory cytokines and oxidative markers, were assessed via enzyme‐linked immunosorbent assay (ELISA). The renal pathology was estimated by histopathology. Transcriptomic sequencing combined with bioinformatics analysis identified the downstream pathway regulated by SQJZ in colon tissues. In vitro, after treatment with CHAC1 knockdown or HIF‐1α activation, lipopolysaccharide (LPS)‐treated NCM460 cells were analyzed for apoptosis, detected by flow cytometry, and inflammatory marker levels, determined by ELISA.
Results
SQJZ significantly reduced serum BUN, SCR, and urinary ACR in CKD rats, ameliorating histopathological damage. In colon tissues, SQJZ suppressed proinflammatory cytokines, including interleukin‐1β (IL‐1β), IL‐6, and tumor necrosis factor‐α (TNF‐α), and oxidative markers, reactive oxygen species (ROS), and malondialdehyde (MDA), while elevating superoxide dismutase activity. Transcriptomics revealed SQJZ‐mediated regulation of HIF‐1. CHAC1 knockdown in vitro reduced LPS‐induced apoptosis and inflammation, while HIF‐1α activation reversed these effects. Additive suppression of inflammation was observed in NCM460 cells with combined CHAC1 knockdown and SQJZ treatment.
Conclusion
SQJZ alleviates intestinal inflammation in CKD, potentially mediated by downregulation of CHAC1 and subsequent inactivation of the HIF‐1 pathway, positioning SQJZ as a promising gut‐targeted therapy in CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Blood Purification, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Clinical Research Academy of Chinese Medicine, No. 16, Airport Road, Guangzhou City 510400, Guangdon…
- Department of Comprehensive (VIP) Inpatient Ward, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, No.…
- Department of Oncology, Luzhou People's Hospital, Luzhou City 646000, Sichuan Province, China.
- Department of Continuing Education, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Clinical Research Academy of Chinese Medicine, No. 16, Airport Road, Guangzhou City 510400, Guangd…
- Department of Nephrology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Clinical Research Academy of Chinese Medicine, No. 16, Airport Road, Guangzhou City 510400, Guangdong Provin…
ORCID-Profile: Chao Wang
Förderung
- Traditional Chinese Medicine Bureau of Guangdong Province
Zitieren
APA
Li, Z., Wang, J., Lin, Y., Zhang, S., Zhang, L., Wu, X., & Wang, C. (2025). Shengqing Jiangzhuo Capsule Alleviates Intestinal Inflammation in Chronic Kidney Disease by Downregulating CHAC1 to Inactivate the HIF‐1 Pathway. Mediators of Inflammation. https://doi.org/10.1155/mi/2173234
Vancouver
Li Z, Wang J, Lin Y, Zhang S, Zhang L, Wu X, et al. Shengqing Jiangzhuo Capsule Alleviates Intestinal Inflammation in Chronic Kidney Disease by Downregulating CHAC1 to Inactivate the HIF‐1 Pathway. Mediators of Inflammation. 2025. doi:10.1155/mi/2173234
BibTeX
@article{Li2025,
author = {Li, Zhibin and Wang, Jian and Lin, Yanna and Zhang, Shu and Zhang, Liangyou and Wu, Xingbo and Wang, Chao},
title = {Shengqing Jiangzhuo Capsule Alleviates Intestinal Inflammation in Chronic Kidney Disease by Downregulating CHAC1 to Inactivate the HIF‐1 Pathway},
journal = {Mediators of Inflammation},
year = {2025},
doi = {10.1155/mi/2173234}
}
EUVIMED